XSPRAY Stock Overview A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Xspray Pharma AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Xspray Pharma Historical stock prices Current Share Price SEK 42.40 52 Week High SEK 91.70 52 Week Low SEK 33.00 Beta 0.85 1 Month Change 0.47% 3 Month Change -13.56% 1 Year Change 10.13% 3 Year Change -36.43% 5 Year Change -48.73% Change since IPO 35.03%
Recent News & Updates Xspray Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 135.04904 million. Dec 02
Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million. Nov 07
Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025 Oct 22
Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025 Oct 21
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission Sep 19 See more updates Xspray Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 135.04904 million. Dec 02
Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million. Nov 07
Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025 Oct 22
Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025 Oct 21
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission Sep 19
New major risk - Financial position Aug 09
Director recently bought kr4.8m worth of stock Jul 31
Price target decreased by 24% to kr91.50 Jul 31
New major risk - Share price stability Jul 29
Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose Jul 10
Director recently bought kr143k worth of stock Jul 05
Now 32% undervalued Jul 01
Now 23% undervalued Jun 17
Price target decreased by 11% to kr107 Jun 16
New minor risk - Share price stability Jun 12
Insufficient new directors Jun 02
Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib May 24
Director recently bought kr504k worth of stock May 21
Chief Executive Officer recently sold kr75k worth of stock May 08
Chairman exercised options to buy kr24m worth of stock. May 05
Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 Mar 28
New minor risk - Share price stability Mar 21
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully Feb 25 Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024
New major risk - Revenue and earnings growth Feb 16
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA Feb 13 Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR
Director recently bought kr2.1m worth of stock Jan 21
Independent Director exercised options to buy kr97k worth of stock. Dec 03
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage Nov 22
Director recently bought kr5.0m worth of stock Nov 16
Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies Nov 10 Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024
New major risk - Financial position Sep 20
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer Sep 16 Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch Sep 12
Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024 Aug 03
Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA Jul 12
Price target decreased by 21% to kr106 May 08
Chief Executive Officer recently sold kr2.2m worth of stock Mar 15
Director recently bought kr135k worth of stock Mar 04 Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023
Director recently bought kr2.6m worth of stock Dec 02
Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia Dec 01
Forecast to breakeven in 2024 Nov 16 Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023
Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer Jun 16
Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors May 20
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate May 11
Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023 May 07
Price target decreased to kr116 Apr 27
Forecast to breakeven in 2024 Apr 27
Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022 Feb 19
Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022 Feb 08
We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth Feb 01
Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™ Jan 14
Price target decreased to kr116 Nov 26
No longer forecast to breakeven Nov 24
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate Oct 26
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate Jun 20
Independent Chairman of the Board Michael Jensen has left the company May 26
We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely Mar 19
New 90-day low: kr113 Mar 06
Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021 Feb 18
Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares? Feb 12
New 90-day low: kr114 Feb 06
Chief Executive Officer exercised options and sold kr3.6m worth of stock Jan 28
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started Jan 24
New 90-day low: kr127 Jan 18
Xspray Pharma Announces Results from Additional Bioequivalence Study Jan 15
Xspray Pharma’S Hynap-Nilo Receives Fda Orphan Drug Designation for the Treatment of Chronic Myeloid Leukemia Dec 30
New 90-day high: kr196 Dec 30
Xspray Pharma AB (publ) Decides to Await the Result of Two Ongoing Clinical Studies Before Submitting Its Anda Application Dec 13
Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation Dec 04 Xspray Pharma AB (publ) to Report Q1, 2021 Results on May 06, 2021
Independent Chairman of the Board recently sold kr1.4m worth of stock Oct 02
Xspray Pharma AB Announces Positive Preliminary Results from the Study for Its Lead Product Candidate HyNap-Dasa Sep 26 Shareholder Returns XSPRAY SE Biotechs SE Market 7D -3.1% 1.1% -3.3% 1Y 10.1% 14.6% 4.8%
See full shareholder returns
Return vs Market: XSPRAY exceeded the Swedish Market which returned 4.8% over the past year.
Price Volatility Is XSPRAY's price volatile compared to industry and market? XSPRAY volatility XSPRAY Average Weekly Movement 7.6% Biotechs Industry Average Movement 9.9% Market Average Movement 5.6% 10% most volatile stocks in SE Market 11.3% 10% least volatile stocks in SE Market 3.2%
Stable Share Price: XSPRAY has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: XSPRAY's weekly volatility (8%) has been stable over the past year.
About the Company Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Show more Xspray Pharma AB (publ) Fundamentals Summary How do Xspray Pharma's earnings and revenue compare to its market cap? XSPRAY fundamental statistics Market cap SEK 1.42b Earnings (TTM ) -SEK 258.05m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) XSPRAY income statement (TTM ) Revenue SEK 0 Cost of Revenue SEK 0 Gross Profit SEK 0 Other Expenses SEK 258.05m Earnings -SEK 258.05m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) -7.64 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 0%
How did XSPRAY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 19:46 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dan Akschuti Pareto Securities Filip Einarsson Redeye
Show 0 more analysts 
